Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Soligenix, Inc. - Common Stock (NQ:SNGX)

1.420 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Soligenix, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Highlights Key Clinical Progress and Reports Q3 2025 Financial Results
Via Investor Brand Network
Surface Sugars on Immune Cells Linked to the Progression of Psoriasis
Via Investor Brand Network
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Eyes Dermatology Market with SGX302’s Encouraging Early Results
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Strengthens Financial Foundation to Advance Multiple Value Drivers
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Strengthens Advisory Leadership in Cutaneous T-Cell Lymphoma
Via Investor Brand Network
Topics Retirement
$37.5M Grant Announced to Boost Management of Infectious Diseases in the US
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Research Highlights Breakthrough in High-Temperature Vaccine Stability
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Advances HyBryte(TM) as Potential First-Line CTCL Treatment with Promising FLASH Results
Via Investor Brand Network
Researchers Develop Nanoparticles That Could Combat Scarring, Inflammation in ARLD
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Updates U.S. Medical Advisory Board to Advance Phase 3 Development of HyBryte for CTCL
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Closes Multimillion-Dollar Public Offering to Fund Pipeline Through 2026
Via Investor Brand Network
How You Can Support Your Loved One Undergoing Cancer Treatment
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board, Advances Phase 3 Study to Support HyBryte(TM) Development for CTCL
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Reports Positive Safety Review from DMC in Ongoing Phase 3 FLASH2 Study of HyBryte for CTCL
Via Investor Brand Network
Rapid Spread of ‘Nightmare Bacteria’ Triggers Alarm
Via Investor Brand Network
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Closes $7.5 Million Public Offering to Extend Cash Runway Through 2026
Via Investor Brand Network
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Expands European Medical Advisory Board to Advance HyBryte Phase 3 Study
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Advances Psoriasis Trial with Encouraging Patient Results, Market Potential
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Strengthens Position in CTCL Treatment with HyBryte(TM) FLASH Results
Via Investor Brand Network
BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Appoints Tomas J. Philipson, PhD as Strategic Advisor
Via Investor Brand Network
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Leveraging Positive Clinical Data to Shape Pivotal SGX942 Trial
Via Investor Brand Network
UCLA Researchers Receive $2M Grant to Study MRI-Guided Cancer Radiation Therapy
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Showcases Expanding Rare Disease, Public Health Pipeline in Latest Corporate Presentation
Via Investor Brand Network
Senior NIH Officials Allege Retaliation as Motive for Their Ouster
Via Investor Brand Network
Topics Whistleblower
BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Publishes Data Demonstrating Two-Year Stability of ThermoVax Ebolavirus Vaccines
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Treatment with FDA Orphan Designation
Via Investor Brand Network
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) CEO to Present at H.C. Wainwright Global Investment Conference
Via Investor Brand Network
Study Explains Why Blood Clotting is Common in IBD Patients
Via Investor Brand Network
Soligenix Inc. (NASDAQ: SNGX) Reports Major Clinical Trial Milestones, Strategic Progress in Rare Disease Treatment Pipeline
Via Investor Brand Network
Synergy Corp. (NASDAQ: SNYR) 1,600+ Nationwide Store Rollout – PPCB, SNGX, BTAI, HIT + Other Disruptive Stocks Moving Now!
Via AB Newswire
Topics Artificial Intelligence
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.